LIBERA BIO
Aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | €335k | Grant | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| % EBITDA margin | - | (12 %) |
| Profit | 0000 | 0000 |
| % profit margin | - | (9 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Libera Bio is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary nanotechnology. The company specializes in enabling biologics, such as antibodies, to cross cell membranes and reach intracellular targets, thereby enhancing the efficacy of cancer therapies. Operating primarily in the oncology sector, Libera Bio collaborates with biopharma partners to develop breakthrough treatments that can be administered intravenously and deliver therapeutic agents directly to tumor and metastatic cells. The business model revolves around strategic partnerships and licensing agreements, generating revenue through collaborative research, development milestones, and royalties from commercialized products. Libera Bio serves a global market, with a particular focus on North America, and aims to provide innovative solutions to unmet medical needs in cancer therapy.
Keywords: nanotechnology, biologics, cancer therapy, oncology, intracellular delivery, antibodies, tumor cells, metastatic cells, biopharma partnerships, intravenous administration.